StockTipsArenaBeta

BUY Mankind Pharma Limited — Prakash Gaba

BUYMankind Pharma Limited

byPrakash GabaHorizon: NA (inferred Swing (≤2wk))24 Sept 2026via CNBC Awaaz.

Entry₹2,488.3Inferred
Target₹2,550
Total upside +2.48%
Stop loss₹2,450-1.54% risk
CMP₹2,474.922h ago
Active-0.54%+3.03%upside left 13d left
Follow Prakash Gaba for new calls(32% target hit, 243 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 3 other Swing calls on MANKINDSee 311 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Sept, 2:59 pm IST
6 supporting3 neutral0 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·26 Sept · today

Past week's volume 1.6× the 30-day average

Technicals · volume·25 Sept · yesterday

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·24 Sept · 2d ago

Mankind Pharma shares up 10% in just 4 sessions; Kotak upgrades the stock - Target, share price trend

NewsLivemint·22 Sept · 4d ago

(opens in new tab)

Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the street

NewsCnbc-Tv18·22 Sept · 4d ago

(opens in new tab)
Neutral / worth noting (3)

Mankind Pharma Gets 68.21 ESG Rating From Niche99 In Leader Category

NewsGoogle News·16 Sept · 1w ago

(opens in new tab)

Mankind Pharma to attend three investor conferences in September 2026

NewsGoogle News·11 Sept · 2w ago

(opens in new tab)

Mankind Pharma to meet investors in Mumbai on June 1-2

NewsGoogle News·11 Sept · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.